Dernières nouvelles pour IREN (NASDAQ:IREN) Stock

IREN

Iris Energy

IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.

IREN Ltd

Iren SpA

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related expenses payable by the Company.
The investors in the Offering include existing healthcare-focused institutional investors, executive officers, and members of the Company's Board of Directors.

News

Offerings

CADL

Candel Therapeutics Announces $15M Registered Direct Offering Of 3.2M Shares At $4.67 Per Share

Deutsche Bank analyst Matthew Niknam maintains CommScope Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) with a Hold and raises the price target from $6 to $7.5.

Price Target

Analyst Ratings

COMM

Deutsche Bank Maintains Hold on CommScope Holding Co, Raises Price Target to $7.5

22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced major updates to its Pinnacle product manufacturing and marketing agreement with its top-5 c-store chain customer, including the launch of four new Pinnacle SKUs, including two in the low nicotine product category. The agreement includes a merchandising agreement to potentially expand the availability of Pinnacle products to include other retail and c-store chains.
The new agreement includes two partner VLN products, Pinnacle VLN&#xAE; Gold cigarettes and Pinnacle Menthol VLN&#xAE; cigarettes which will be sold at approximately 1,700 stores across 27 states. Sales to customers are expected to begin in late summer and early fall of 2025, with stocking orders in advance, as state approvals are secured.

XXII

22nd Century Announces Updates To Pinnacle Product Manufacturing And Marketing Agreement With Top-5 C-Store Chain Customer; Launches Pinnacle VLN And Moist Snuff Products In More Than 1,700 Stores Across 27 States

<a href="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm" title="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm">https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm</a>

Guidance

Schlumberger N.V. Says Looking Broadly Across Energy Markets, There Has Been A Lot Of Uncertainty This Quarter; Commitment To Returning A Minimum Of $4B To Shareholders In 2025 Is Unchanged

Cantor Fitzgerald analyst Matthew Prisco maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Overweight and raises the price target from $90 to $105.

Cantor Fitzgerald Maintains Overweight on Teradyne, Raises Price Target to $105

Homeowners have on average, $181,000 in equity. This new product helps them access it before transitioning to a new home
DETROIT, June 24, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=3636688888&amp;u=https%3A%2F%2Frocket.com%2Fmortgage%2F&amp;a=Rocket+Mortgage">Rocket Mortgage</a>, the nation's largest mortgage lender and a part of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=1515700121&amp;u=https%3A%2F%2Fwww.rocketcompanies.com%2F&amp;a=Rocket+Companies">Rocket Companies</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), today announced the launch of bridge loans – a strategic solution designed to help buyers wrestle back control in today's competitive housing market. This new product allows current homeowners to use equity to compete shoulder-to-shoulder with cash buyers – allowing them to purchase their next primary residence before selling their current one. This provides both financial flexibility and eliminates the uncertainty and reluctance of home sellers that often comes with so-called 'contingent' offers.
With high home prices and tight housing inventory, many buyers struggle to compete without first selling – leading to delays and missed opportunities. Yet the average homeowner has $181,000 in untapped equity, a powerful resource to make a strong offer.¹ &nbsp;Rocket Mortgage's bridge loan unlocks that equity upfront, providing funds for a down payment or closing costs in the interim.

Rocket Mortgage Launches Bridge Loans To Help Homeowners Access Equity And Compete With Cash Buyers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs lowered Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) price target from $48 to $46. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Advance Auto Parts shares closed at $51.93 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim increased the price target for Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from $50 to $68. Guggenheim analyst Seamus Fernandez maintained a Buy rating. Cidara Therapeutics shares closed at $44.95 on Monday. <a href="https://www.benzinga.com/quote/CDTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) price target from $15 to $20. Needham analyst Serge Belanger maintained a Buy rating. CorMedix shares closed at $16.56 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/CRMD/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Lyell Immunopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) from $1 to $10. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Neutral rating. Lyell Immunopharma shares closed at $8.99 on Monday. <a href="https://www.benzinga.com/quote/LYEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $199 to $179. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut DICK&#8217;S Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) price target from $250 to $240. B of A Securities analyst Robert Ohmes maintained a Buy rating. DICK&#8217;S Sporting shares settled at $175.79 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MACOM Technology Solutions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) price target from $250 to $270. B of A Securities analyst Vivek Arya maintained a Buy rating. MACOM Technology Solutions shares closed at $138.65 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) price target from $220 to $240. Keybanc analyst Steve Barger maintained an Overweight rating. Westinghouse Air Brake Technologies shares closed at $202.19 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from $200 to $220. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Applied Materials shares settled at $171.96 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald increased Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $90 to $115. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Lam Research shares closed at $91.61 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png" alt="" class="wp-image-959828" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

AMAT

CDTX

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Cantor Fitzgerald analyst Matthew Prisco maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Neutral and lowers the price target from $110 to $90.

ONTO

Cantor Fitzgerald Maintains Neutral on Onto Innovation, Lowers Price Target to $90

Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis
No new safety signals observed
SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN&#xAE;&nbsp;(valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025.
The Phase 3 GENEr8-1 trial demonstrated that durable bleed control and sustained factor VIII (FVIII) expression were maintained five years after treatment with ROCTAVIAN. FVIII activity remained consistent with previously reported results, and no new safety signals were observed. Across the entire trial, no participants developed FVIII inhibitors or experienced thromboembolic events, and there were no treatment-related malignancies across the five years of the study.

BMRN

BioMarin Pharma Presents New Data Underscoring Long-Term Efficacy And Safety Of ROCTAVIAN At Congress Of ISTH

Contracts

ASNS

Actelis Receives Initial Order From A Telecommunications Carrier To Deploy Its GigaLine Solutions

GSK Announces FDA Approval Of Benlysta Autoinjector For children With Active Lupus Nephritis

PPSI

Pioneer Power Solutions Bags ~$10M Award From U.S. Charging-As-A-Service Company To Accelerate e-Boost Deployment

Cantor Fitzgerald analyst Matthew Prisco maintains Nova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) with a Overweight and raises the price target from $250 to $300.

NVMI

Cantor Fitzgerald Maintains Overweight on Nova, Raises Price Target to $300

Company research targets topical application for treatment of skin cancers
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54281272&amp;newsitemid=20250624870760&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=a85c3afa960a05417f2274483ca882b6">bioAffinity Technologies, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane.
The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the Company's new U.S. Patent No. 12,305,171.
The invention uses small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro research demonstrates this siRNA-driven double knockdown effectively targets cancer cells from multiple tumor types, including lung, breast, prostate, brain, and skin, without harming normal cells, suggesting a universal mechanism of action.
bioAffinity is exploring the application of this technology as a topical treatment specifically designed for cutaneous malignancies and neoplasms of the skin. This development aligns closely with the Company's broader strategy of addressing cancer through both early-stage diagnostics, exemplified by CyPath&#xAE; Lung, and innovative therapeutic approaches.
bioAffinity continues to advance its high-growth core diagnostic platform, CyPath&#xAE; Lung, an accurate, noninvasive test for early-stage lung cancer detection, while simultaneously leveraging its scientific expertise toward novel therapeutic solutions that address critical unmet medical needs in oncology.

BIAF

CNIPA Issues Notification Of Patent Grant For bioAffinity Technologies' Composition And Method For Selectively Killing Cancer By Targeting CD320 And LRP2 Receptors On Cell Membrane

CAPR

Capricor Therapeutics Provides Update On Deramiocel BLA, Says FDA Has Indicated An Advisory Committee Meeting Is Not Required At This Time

Cantor Fitzgerald analyst Matthew Prisco maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Overweight and raises the price target from $110 to $120.

MKSI

Cantor Fitzgerald Maintains Overweight on MKS, Raises Price Target to $120

InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) stock is surging early Tuesday, with a session volume of 6.63 million compared to the average volume of 1.31 million, as per <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
On Tuesday, InMed released new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">candidate for Alzheimer&#8217;s disease</a>.
The study evaluated INM-901 in an ex vivo model of lipopolysaccharide (LPS)-induced inflammation in animal brain tissue, which is designed to induce a strong expression of pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/46070338/inmeds-inm-901-significantly-reduces-neuroinflammation-in-alzheimers-disease-ex-vivo-study" rel="noreferrer noopener">inflammasome marker NLRP3</a>.
Results demonstrated that INM-901 treatment can reduce pro-inflammatory cytokines and may directly impact neuroinflammation independent of the influence of amyloid beta or tau aggregation.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43101528/why-inmed-pharmaceuticals-inm-stock-is-skyrocketing" rel="noreferrer noopener">Why InMed Pharmaceuticals (INM) Stock Is Skyrocketing</a>
This study model offers insight into INM-901&#8217;s potential therapeutic impact on brain inflammation that may underlie a broad range of neurodegenerative diseases, including Alzheimer&#8217;s disease.
Key Findings from the Study
INM-901 significantly reduced levels of NLRP3 and IL-1β, two inflammasome markers increasingly implicated in the pathogenesis of Alzheimer&#8217;s disease and other neuroinflammatory diseases.
INM-901 treatment resulted in a dose-dependent and statistically significant reduction in several key pro-inflammatory markers, including IL-6, IL-1β, KC/Gro, and IL-2.
INM-901 reduced key pro-inflammatory markers independent of amyloid-beta or tau pathology, which indicates potential for treating other dementia-related diseases.
NLRP3 has been implicated in the pathogenesis of several inflammatory, autoimmune, metabolic, and neurodegenerative conditions such as Alzheimer&#8217;s disease, Parkinson&#8217;s, type 2 diabetes, and others.
In these diseases, overactivation of NLRP3 can result in chronic inflammation in the brain, which may contribute to neurodegeneration and cognitive decline.
Key characteristics of INM-901 include
Reduced neuroinflammation and improved neurite growth and neuronal function, indicating the potential to restore damage caused by Alzheimer&#8217;s disease.
It is a preferential signaling agonist of the CB1/CB2 receptors and has been shown to have neuroprotective effects, helping protect the neurons in the brain from damage and cell death.
Impacts the peroxisome proliferator-activated receptors (&#8220;PPARs&#8221;), which have been shown to play an essential role in diabetes and are also considered as one of the potential therapeutic targets for neurodegenerative disorders such as Alzheimer&#8217;s disease;
It <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40464303/inmed-pharmaceuticals-advances-oral-candidate-for-alzheimers-disease-stock-surges-on-tuesday" rel="noreferrer noopener">can be administered orally</a> and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection, offering many potential advantages over the routes of administration of the currently approved products.
Long-term preclinical behavioral studies demonstrate significant improvement in cognitive function, memory, locomotor activity, anxiety-based behavior, and sound awareness.
Price Action: INM stock is up 70% at $4.17 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/01/43167375/vigil-neurosciences-alzheimers-candidate-shows-encouraging-safety-profile-plans-to-start-mid-stage-study-in-q3" target="_blank" rel="noreferrer noopener">Vigil Neuroscience&#8217;s Alzheimer&#8217;s Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

General

Why InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge

Macro Economic Events

Econ #s

Economics

US House Price Index (YoY) (Apr) +3% vs +3.9% Prior

7 analysts have expressed a variety of opinions on MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $138.57, a high estimate of $160.00, and a low estimate of $120.00. Highlighting a 7.11% decrease, the current average has fallen from the previous average price target of $149.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1750770066_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of MACOM Technology Solns's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MACOM Technology Solns. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MACOM Technology Solns compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of MACOM Technology Solns's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MACOM Technology Solns's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MTSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MACOM Technology Solns analyst ratings.</a>
<h2>All You Need to Know About MACOM Technology Solns</h2>
MACOM Technology Solutions Holdings Inc is a provider of analog, digital, and mixed-signal semiconductor solutions to original equipment manufacturers and distributors. These solutions are found in systems for industrial, medical, scientific, and test and measurement markets. The firm's portfolio of products includes integrated circuits, multichip modules, power pallets and transistors, diodes, amplifiers, switches and switch limiters, passive and active components, and complete subsystems. Roughly a third of the firm's revenue is generated in the United States, with the rest coming from China, Japan, Singapore, South Korea, and other countries across the world.
<h3>Financial Milestones: MACOM Technology Solns's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: MACOM Technology Solns's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 30.16%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: MACOM Technology Solns's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 13.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.69%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): MACOM Technology Solns's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: MACOM Technology Solns's debt-to-equity ratio stands notably higher than the industry average, reaching 0.44. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On MACOM Technology Solns Through 7 Analysts

In the latest quarter, 14 analysts provided ratings for Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.29, a high estimate of $23.00, and a low estimate of $14.00. Highlighting a 1.08% decrease, the current average has fallen from the previous average price target of $19.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1750770058_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Levi Strauss. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Drew Crum</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Levi Strauss. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Levi Strauss compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Levi Strauss's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LEVI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Levi Strauss analyst ratings.</a>
<h2>Discovering Levi Strauss: A Closer Look</h2>
Levi Strauss &amp; Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss &amp; Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
<h3>Levi Strauss: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Levi Strauss's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.15% as of 28 February, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Levi Strauss's ROE excels beyond industry benchmarks, reaching 6.74%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Levi Strauss's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Levi Strauss's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LEVI

Forecasting The Future: 14 Analyst Projections For Levi Strauss

Press Releases

IREN Business Update

IREN March 2025 Monthly Update

IREN capacity increased to 40 EH/s

IREN to Release Q3 FY25 Results on May 14, 2025

IREN April 2025 Monthly Update

Earnings

IREN Reports Q3 FY25 Results

IREN May 2025 Monthly Update

Financing

IREN announces proposed convertible notes offering

IREN prices upsized $500 million convertible notes offering

IREN closes upsized $550 million convertible notes offering

Agilysys

C3.ai

Alkami Technology

Alarm.com Holdings

Asana

BlackLine

Blackbaud

Braze

Bitdeer Technologies Group - Ordinary Shares

Bitdeer Technologies

Cleanspark

Core Scientific

Sprinklr

EverCommerce

Five9

Hut 8

Ncino

NextNav

Opera Limited - American Depositary Shares

Opera

LiveRamp Holdings

Riot Platforms

RingCentral

Sapiens International Corporation N.V. - Common Shares

Sapiens International

NCR Voyix

Workiva

Clear Secure

Canaccord Genuity

B. Riley Securities

Macquarie

HC Wainwright & Co.

JP Morgan

Comments

IREN

Actualités

Dernières nouvelles pour IREN (NASDAQ:IREN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL